G-CSF Prevents Progression of Diabetic Nephropathy in Rat

Byung-Im So1,9, Yi-Sun Song1,9, Cheng-Hu Fang2,3, Jun-Young Park1, Yonggu Lee2, Jeong Hun Shin2, Hyuck Kim4, Kyung-Soo Kim1,2,*

1 Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Korea, 2 Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea, 3 Department of Internal Medicine, Yanbian University, College of Medicine, Yanji, China, 4 Department of Thoracic and Cardiovascular Surgery, Hanyang University College of Medicine, Seoul, Korea

Abstract

Background: The protective effects of granulocyte colony-stimulating factor (G-CSF) have been demonstrated in a variety of renal disease models. However, the influence of G-CSF on diabetic nephropathy (DN) remains to be examined. In this study, we investigated the effect of G-CSF on DN and its possible mechanisms in a rat model.

Methods: Otsuka Long-Evans Tokushima Fatty (OLETF) rats with early DN were administered G-CSF or saline intraperitoneally. Urine albumin creatinine ratio (UACR), creatinine clearance, mesangial matrix expansion, glomerular basement membrane (GBM) thickness, and podocyte foot process width (FPW) were measured. The levels of interleukin (IL)-1β, transforming growth factor (TGF)-β1, and type IV collagen genes expression in kidney tissue were also evaluated. To elucidate the mechanisms underlying G-CSF effects, we also assessed the expression of G-CSF receptor (G-CSFR) in glomeruli as well as mobilization of bone marrow (BM) cells to glomeruli using sex-mismatched BM transplantation.

Results: After four weeks of treatment, UACR was lower in the G-CSF treatment group than in the saline group (p<0.05), as were mesangial matrix expansion, GBM thickness, and FPW (p<0.05). In addition, the expression of TGF-β1 and type IV collagen and IL-1β levels was lower in the G-CSF treatment group (p<0.05). G-CSFR was not present in glomerular cells, and G-CSF treatment increased the number of BM-derived cells in glomeruli (p<0.05).

Conclusions: G-CSF can prevent the progression of DN in OLETF rats and its effects may be due to mobilization of BM cells rather than being a direct effect.

Introduction

Diabetes mellitus (DM) is a multisystem disorder that affects various organs. Almost 50% of DM patients develop diabetic nephropathy (DN), despite control of blood glucose and/or blood pressure. DN is widely recognized as a common cause of end-stage renal disease [1,2]. It is characterized clinically by proteinuria accompanied by decreased glomerular filtration rate (GFR) [1,3]. In addition, it is histologically defined by glomerular basement membrane (GBM) thickening and mesangial matrix expansion with the accumulation of extracellular matrix proteins [4,5].

Granulocyte colony-stimulating factor (G-CSF) is frequently used to mobilize hematopoietic stem cells from the bone marrow (BM) into the peripheral blood [6]. In a previous clinical study, G-CSF was employed to accelerate recovery from febrile neutropenia after cytotoxic therapy and to harvest donor cells in peripheral blood after BM transplantation (BMT) [7]. Recently, experimental studies have demonstrated the beneficial effects of G-CSF in the kidney, brain, liver, and heart. For example, one study showed that G-CSF increased angiogenesis and reversed ischemic damage in the brain [8]. In other studies, G-CSF protected against renal tubular injury induced by adriamycin [9] and against hepatic steatosis [10], as well as diabetic cardiomyopathy in rats [11]. Flaquer M, et al. demonstrated that the combination of hepatocyte growth factor gene therapy with hematopoietic stem cell mobilization by G-CSF may contribute to renal tissue repair and regeneration in diabetes-induced mice [12]. However, the effect of G-CSF itself on DN is unknown. In this study, we evaluated the effects of G-CSF on early DN using Otsuka Long-Evans Tokushima Fatty (OLETF) rats and investigated possible mechanisms underlying the beneficial effects.

Materials and Methods

Animals

The experiments were performed in compliance with the ARRIVE guidelines on animal research [13], and all protocols were approved by the Hanyang University Institutional Animal...
Care and Use Committee. We used OLETF rats and control Long-Evans Tokushima Otsuka (LETO) rats, supplied by Otsuka Pharmaceutical Co. (Tokushima, Japan). OLETF rats were developed as spontaneous long-term hyperglycemic rats with type 2 DM; they have also been used to model aspects of metabolic syndrome, such as obesity and fatty liver [14]. The rats were kept in a specific pathogen-free facility at the Hanyang University Medical School Animal Experiment Center at a controlled temperature (23°C ± 2°C) and humidity (55% ± 5%), with a 12-hr artificial light/dark cycle.

Development of the DN Model

Starting at 16 weeks of age, all male OLETF rats (n = 12) received water containing 30% sucrose ad libitum to facilitate the development of DN. After DN had been induced, they received no more sucrose water. LETO rats (n = 7), as normal controls, received tap water without 30% sucrose. The DN model was confirmed by serum fasting glucose level exceeding 200 mg/dl, urine albumin creatinine ratio (UACR) exceeding 300 mg/g, and histologically-confirmed GBM thickening and mesangial matrix expansion [15–17]. To detect the development of the DN model, body weights, serum glucose levels, and urine albumin levels of all the rats were measured at 4 week intervals from 16 to 38 weeks of age. After 22 weeks of sucrose feeding (at 38 weeks of age), three male OLETF and three male LETO rats were sacrificed for histological examination. One OLETF rat died during development of the DN model. To test the effect of G-CSF on DN, we used eight male OLETF rats and four male LETO rats. The experimental design is outlined in Fig. 1.

| Table 1. Sequences of primers. |
|-----------------------------|-----------------------------|
| Primer          | Sequences                      | Size(bp)  |
| G-CSFR F:      | 5'-CCA-TTG-TCC-ATC-CTC-GGG-ATC-3' | 234       |
| R:            | 5'-CTT-TGG-TCT-TGG-CTG-ATG-3'   |           |
| β-actin F:     | 5'-ACC-TTC-AAC-CCA-GCC-ATG-ATG-3' | 698       |
| R:            | 5'-TGTT-ATC-ATC-TCT-TGG-AAG-ACG-3' |           |
| TGF-β1 F:      | 5'-TGG-TCT-TAC-ATA-CTC-GTA-ATC-3' | 102       |
| R:            | 5'-GGT-GGT-GCT-GGA-CAA-GGT-3'   |           |
| Type IV collagen F: | 5'-GAG-GGT-GCT-GGA-CAA-GCT-3' | 67        |
| R:            | 5'-GAT-GAT-GCT-GGT-AGA-TTA-GTT-3' |           |
| IL-1β F:       | 5'-AAA-ATT-GTC-CAG-CTG-ATG-GTA-3' | 115       |
| R:            | 5'-CAT-TCT-CGC-CTT-GTA-3'       |           |
| GAPDH F:       | 5'-CCT-TCT-TTC-GTA-AGT-GGA-ACA-T-3' | 96        |
| R:            | 5'-GAG-GGG-TAG-AGT-CAT-GTA-GTA-3' |           |

Bone Marrow Transplantation Model

Starting at 6 weeks of age, female OLETF rats received lethal γ-irradiation (3 and 4 Gy, 4 hr apart, total of 7 Gy) from a Gammacell 1000 Elite (MDS Nordion, Ottawa, Canada) [18,19]. On the following day, 2 × 10^8 donor BM cells from male OLETF rats were administered intravenously via the tail vein. Donor BM cells were obtained as described previously [20]. To confirm the

**Figure 1. Experimental design.** Experiment 1: a rat model of diabetic nephropathy (male OLETF rats), Experiment 2: a rat model of diabetic nephropathy with bone marrow transplantation (BMT) (donors: male OLETF rats, recipients: female OLETF rats).

doi:10.1371/journal.pone.0077048.g001
DN model, female OLETF rats (after 4 weeks of recovery from BMT; 10 weeks of age) received tap water containing 30% sucrose ad libitum and certified rodent laboratory chow. After 24 weeks of sucrose feeding (at 34 weeks of age), DN was confirmed in the female rats (data not shown). The experimental design is outlined in Fig. 1.

G-CSF Administration

OLETF rats in which DN had been induced were divided randomly into two groups (G-CSF-treated and saline-treated, n = 4 each), treated daily for 5 days with G-CSF (100 µg/kg per day, Dong-A Pharmacological, Seoul, Korea) or an equal volume of saline (Dai Han Pharm. Co., Ltd., Seoul, Korea), and observed for 4 weeks [21].

Urinate and Blood Chemistry

Before and after G-CSF treatment, we measured serum glucose, total cholesterol (TC), triglyceride (TG), UACR, and creatinine clearance (CrCl). Animals were transferred to individual metabolic cages for urine sample collection, and 24-hours urine samples were collected from the tail vein after 8 hours of fasting, and serum glucose, TC, and TG levels were analyzed with an Olympus AU400 auto analyzer (Olympus GmbH, Hamburg, Germany) [22]. Blood samples were collected from the tail vein after 8 hours of fasting, and serum glucose, TC, and TG levels were analyzed with an Olympus AU400 auto analyzer (Olympus GmbH, Hamburg, Germany) [23].

Histological Examination

Kidney tissue from each animal was fixed in 10% formalin solution (pH 7.4) and embedded in paraffin. The embedded tissue was cut into 3-µm-thick sections and subjected to periodic acid-Schiff (PAS) staining for light microscopic evaluation. Mesangial matrix expansion in the glomeruli was evaluated in PAS-stained sections using Image-Pro Plus 4.5 (Media Cybernetics, Silver Spring, MD) [24]. The mean percent area of PAS-stained glomeruli was calculated for 20 randomly selected fields of each kidney section.

Ultrastructural Examination

For electron microscope examination, the kidneys were fixed in 2.5% glutaraldehyde (0.2 M cacodylate buffer, pH 7.4) and embedded in epoxy resin. Ultrathin sections were double-stained with 1.25% uranium acetate and 0.4% lead citrate and then observed with an electron microscope (H-7600 s, Nikon, Tokyo, Japan). GBM thickness was determined in the glomeruli where the epithelial and endothelial cells were clearly visible. A perpendicular line of GBM was drawn from the endothelial to the epithelial edge, and it was measured by image analysis using Image-Pro Plus 4.5 (Media Cybernetics, Silver Spring, MD) [25]. The mean GBM thickness was calculated for 20 randomly selected fields of each kidney section. To examine podocyte foot process width (FPW), the mean of FPW was calculated as described previously [26,27]: FPW = \( \frac{\pi}{4} \times \left( \frac{\text{GBM length}}{\sum \text{foot process}} \right) \), where GBM length is the total peripheral GBM length in each image, and \( \sum \) foot process is the total foot processes number on peripheral GBM in each image. The correction factor \( \frac{\pi}{4} \) was used to correct for presumed random variation in the angle of section relative to the long axis of the podocyte. The mean of FPW was determined from the images at 10,000 x magnification of each kidney section.

Reverse Transcriptase-polymerase Chain Reaction (RT-PCR) Analysis of G-CSF Receptor (G-CSFR) Gene Expression

Kidneys were frozen in liquid nitrogen and stored at −80°C for the RT-PCR assays. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, USA), and then reverse transcribed using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, USA) according to the manufacturer’s protocol. We performed RT-PCR to analyze G-CSFR and β-actin. The sequences of the rat primer pairs for G-CSFR and β-actin and the original clones are listed in Table 1. PCR was carried out for 30 cycles of denaturation at 90°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 1 min. The RT-PCR products were visualized by electrophoresis on 1.5% (w/v) agarose gels using Gel-Doc 2000 (Bio-Rad, CA, USA).

Quantitative Real-time PCR Analysis of TGF-β1, IL-1β, and Type IV Collagen Gene Expression

Quantitative real-time PCR (qPCR) was performed using SYBR Green qPCR Mix (Toyobo, Tokyo, Japan) and analyzed on a LightCycler 1.5 (Roche Diagnostics, Indianapolis, IN, USA). The genes selected were transforming growth factor (TGF)-β1 (TGF-β1), type IV collagen, and interleukin (IL)-1β (IL-1β)
qPCR amplification was performed by incubation for 10 min at 95°C followed by 45 cycles of 10 s at 95°C, 10 s at 60°C, and 10 s at 72°C, and a final dissociation step at 65°C for 15 s. The crossing point of each sample was automatically determined by the LightCycler program, and the relative change ratio was determined using the ratio of the mRNA for the selected gene to that of glyceraldehyde-3-phosphate dehydrogenase [10].

PCR analysis was performed in duplicate.
Immunohistochemical Staining for ED-1 and G-CSFR

To confirm the presence of macrophages in glomeruli, immunohistochemical staining was performed on the kidneys of female rats that had received BM from male rats. We used a mouse monoclonal anti-monocyte/macrophage (ED-1) (1:100 dilution; Serotec, Oxford, UK) or rabbit polyclonal anti-TGF-β1 (1:200 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) antibodies as the primary antibody. ED-1 and TGF-β1 levels were detected with streptavidin-peroxidase and peroxidase substrate solution (Dako, Copenhagen, Denmark). For ED-1, the numbers of positively stained macrophages were counted under high magnification (x400) in 120 to 130 glomeruli of each kidney section by image analysis using Image-Pro Plus 4.5 (Media Cybernetics, Silver Spring, MD) [28]. Images were obtained on a Leica DM4000B microscope equipped with a Leica DFC310 FX camera and LAS Basic V3.8 software (Leica Microsystems, Wetzlar, Germany). To identify G-CSFR in the glomeruli of each kidney section, we performed immunofluorescence staining. Tissue sections were incubated for 90 min with a mouse monoclonal anti-G-CSFR antibody as the primary antibody (1:100 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). The sections were washed and then incubated with fluorescein isothiocyanate-conjugated secondary antibody (1:500 dilution; Abcam, Cambridge, MA, USA) for 60 min. Images were obtained on an ECLIPSE 80i microscope equipped with an iAi progressive scan camera (Nikon, Tokyo, Japan) and CytoVision system software (Applied Imaging, Newcastle, UK).

Fluorescence in situ Hybridization (FISH) Analysis of the Y Chromosome

To detect donor BM cells in recipient kidneys, the Y chromosome was detected by FISH in female rats. Cy3-labeled rat Y chromosomes (ID Labs Inc, London, Ontario, Canada) were provided in the supplier’s hybridization mix. FISH analysis was performed using iDetectTM according to the manufacturer’s recommendations. The Y-chromosome positive cells were calculated for ten randomly selected glomeruli of each kidney section. Images were obtained on an ECLIPSE 80i microscope equipped with an iAi progressive scan camera (Nikon, Tokyo, Japan) and CytoVision software (Applied Imaging, Newcastle, UK).

| Table 2. Levels of metabolic parameters before treatment with G-CSF or saline. |
|----------------|----------------|----------------|----------------|
| LETO           | OLETF          | LETO           | OLETF          |
| Body weight, g | 530.75 ± 9.84  | 475.13 ± 30.64* | 475.13 ± 30.64* |
| Kidney/body weight, % | 0.29 ± 0.00  | 0.39 ± 0.01*  | 0.39 ± 0.01*  |
| Serum glucose, mg/dl | 118.50 ± 4.04  | 264.75 ± 23.92* | 264.75 ± 23.92* |
| TC, mg/dl       | 94.50 ± 6.76   | 176.38 ± 40.33* | 176.38 ± 40.33* |
| TG, mg/dl       | 38.00 ± 9.83   | 142.63 ± 31.10* | 142.63 ± 31.10* |
| UACR, mg/g      | 6.41 ± 0.34    | 486.59 ± 30.79* | 486.59 ± 30.79* |
| CrCl, ml/min    | 1.60 ± 0.78    | 1.55 ± 0.27    | 1.55 ± 0.27    |

Long-Evans Tokushima Otsuka rats, LETO; Otsuka Long-Evans Tokushima Fatty rats, OLETF; total cholesterol, TC; triglyceride, TG; urine albumin creatinine ratio, UACR. All data are expressed as mean ± SD. *P < 0.05 vs. LETO rat [LETO, n = 4; OLETF, n = 8].

doi:10.1371/journal.pone.0077048.t002

| Table 3. Levels of metabolic parameters after treatment with G-CSF or saline. |
|----------------|----------------|----------------|----------------|
| LETO           | OLETF + saline | OLETF + G-CSF  | LETO           |
| Body weight, g | 583.25 ± 16.07 | 518.36 ± 36.65 | 547.62 ± 30.41* |
| Kidney/body weight, % | 0.24 ± 0.04  | 0.44 ± 0.03*  | 0.36 ± 0.03*  |
| Serum glucose, mg/dl | 214.50 ± 10.21  | 410.75 ± 18.57* | 427.00 ± 12.19* |
| TC, mg/dl       | 104.25 ± 5.25  | 265.00 ± 22.02* | 161.75 ± 55.69* |
| TG, mg/dl       | 49.50 ± 4.20   | 185.00 ± 62.89* | 123.50 ± 23.27* |
| UACR, mg/g      | 8.42 ± 7.58    | 648.77 ± 72.33* | 451.00 ± 122.84* |
| CrCl, ml/min    | 1.64 ± 0.18    | 1.81 ± 0.37    | 1.68 ± 0.47    |

Long-Evans Tokushima Otsuka rats, LETO; Otsuka Long-Evans Tokushima Fatty rats, OLETF; total cholesterol, TC; triglyceride, TG; urine albumin creatinine ratio, UACR. All data are expressed as mean ± SD. *P < 0.05 vs. LETO rat. **P < 0.05 vs. untreated OLETF rat (n = 4).

doi:10.1371/journal.pone.0077048.t003

Statistical Analysis

All data are presented as mean ± SD, except for histological data, which are presented as mean ± SE. Statistical differences were determined with the Statistical Package for the Social Sciences (SPSS) 18.0 software (SPSS Inc., Chicago, IL, USA). Data were analyzed using Mann Whitney U-tests (for single comparisons) or Kruskal-Wallis nonparametric ANOVA (for multiple comparisons). Values of P < 0.05 were considered statistically significant.

Results

Body weight was significantly higher (P < 0.05) in the OLETF rats than the control LETO rats during the first 12 weeks of sucrose feeding (to 28 weeks of age) but was significantly lower (P < 0.05) after 22 weeks of sucrose feeding (at 38 weeks of age) (Fig. 2A). Serum glucose and UACR levels were higher in the OLETF rats than in the control LETO rats at all times (P < 0.05). Serum glucose levels exceeded 200 mg/dl during the first 12 weeks of sucrose feeding and UACR levels exceeded 300 mg/g during the first 16 weeks of sucrose feeding (at 32 weeks of age) (Fig. 2B and C). Kidney/body weight, serum glucose, and UACR levels before treatment were higher in OLETF rats than the control LETO rats (P < 0.05). CrCl levels did not differ between the two groups. Body weight was lower in OLETF rats than in the control LETO rats (P < 0.05). TC and TG levels were higher in OLETF rats than the control LETO rats (P < 0.05) (Table 2). Histologically, mesangial matrix expansion and GBM thickness before treatment were higher in the OLETF rats than the control LETO rats (P < 0.05) (Fig. 3). These changes were evidences of early DN.

Metabolic Parameters

Kidney/body weights and UACR after 4 weeks of treatment were significantly lower in the G-CSF-treated group than in the saline-treated group (P < 0.05) but still higher than the control LETO group. TC levels were lower in the G-CSF-treated group than in the saline-treated group (P < 0.05) and not significantly different from that of the control LETO group. Serum glucose, TG level, and body weight were not significantly different from in the saline-treated group. CrCl levels did not differ significantly within the three groups (Table 3).
Histological Findings

Mesangial matrix expansion after 4 weeks of treatment was lower in the G-CSF-treated group than in the saline-treated group ($P<0.05$) but still higher than the control LETO group ($P<0.05$) (Fig. 4A and C). In addition, electron microscopic examination revealed irregular GBM thickening and podocyte foot process effacements in some parts of the glomeruli (Fig. 4B). GBM thickness and FPW were lower in the G-CSF-treated group than in the saline-treated group ($P<0.05$) and not significantly different from that of the control LETO group (Fig. 4D). FPW was lower in the G-CSF-treated group than in the saline-treated group ($P<0.05$) but still higher than the control LETO group ($P<0.05$) (Fig. 4E).

Expression Levels of TGF-β1, Type IV Collagen, and IL-1β after Treatment

The level of TGF-β1 mRNA was lower in the G-CSF-treated group than in the saline-treated group ($P<0.05$) but still higher than the control LETO group ($P<0.05$) Levels of type IV collagen and IL-1β mRNA were also lower in the G-CSF-treated group than in the saline-treated group ($P<0.05$) and not significantly different from those of the control LETO group (Fig. 5A).

Mechanism of the G-CSF Effect - Y Chromosome-positive Cells within Glomeruli

Y chromosome-positive cells were detected in the glomeruli of the kidney tissue of female rats (Fig. 6A and B). The numbers of Y chromosome cells were higher in the G-CSF-treated group than in the saline-treated group ($P<0.05$) (Fig. 6D). Immunohistochemical staining for TGF-β1 and subsequent quantitative analysis demonstrated that TGF-β1 protein expression was lower in the G-CSF-treated group than in the saline-treated group ($P<0.05$) (Fig. 5B and C).
Mechanism of the G-CSF Effect - G-CSFR Analysis

We confirmed the presence of G-CSFR in kidney tissue by RT-PCR (Fig. 7A). However, immunofluorescence analysis revealed that it was not present in the glomeruli (Fig. 7B).

Discussion

Our data show that G-CSF treatment can prevent progression of early DN in OLETF rats, and that mobilization of BM cells, rather than a direct effect of G-CSF, is the likely explanation for the observed effect.

Previous studies have demonstrated that the characteristic glomerular changes in DN include mesangial matrix expansion, GBM thickening, and podocyte foot process effacement [29]. In our study, the beneficial effects of G-CSF in DN were evident from the histological findings. We confirmed by PAS staining that G-CSF reduced mesangial matrix expansion in kidney tissue. We also confirmed by electron micrographs that G-CSF decreased GBM thickness and podocyte foot process effacement in some parts of the glomeruli. Functionally, we showed that G-CSF decreased UACR level.

According to a previous study, early DN is characterized by increased kidney/body weight and UACR levels and unchanged CrCl level [30]. In our model, kidney/body weight and UACR levels increased, whereas the CrCl level did not change, thus showing that the model could be characterized as early DN.
The pathophysiology of DN involves the accumulation of microvascular matrix protein and inflammation. Previous studies indicated that TGF-β1 played a key role in the development of renal hypertrophy and the accumulation of extracellular matrix components in diabetes, as well as stimulation of the synthesis of extracellular matrix molecules such as type IV collagen [31,32]. Further, inflammatory cytokines such as IL-1β caused inflammation by increasing the expression and synthesis of adhesion molecules [33]. We demonstrated that G-CSF clearly reduced TGF-β1, type IV collagen, and IL-1β mRNA expression.

Previous studies suggested several possible mechanisms for the general effect of G-CSF on renal disease. First, G-CSF may affect
the kidney directly. A direct effect of G-CSF on cardiomyocytes and endothelial cells has been reported [34,35]. In the kidney, only a direct effect of G-CSF on renal tubules, in which express G-CSFR, has been reported [36]. We found by RT-PCR that G-CSFR was present in kidney tissue; however, immunofluorescence analysis revealed that it was not present in mesangial cells, podocytes, or endothelial cells in glomeruli. In this study, we observed that the therapeutic effects of G-CSF, including a decrease in GBM thickness and podocyte foot process effacement, appeared in glomeruli. There results suggest that G-CSF does not directly act through G-CSFR in glomerular cells because G-CSFR is not expressed at mesangial cells, podocytes, and endothelial cells in glomeruli.

As another possible mechanism, increased bone marrow cells homing to injured renal cells could induce trans-differentiation or trophic effects, thereby contributing to renal cell repair. Previous reports suggested that BM cells might trans-differentiate into renal tubular cells that repair kidneys [37]. Prodomidi et al. demonstrated that podocyte regeneration in a renal disease model was improved by paracrine action of bone marrow-derived cells [38]. In addition, the mechanism of G-CSF-induced hematopoietic stem cell mobilization by stromal cell-derived factor (SDF)-1 and CXCR4 interaction was well known [39]. In our sex-mismatched BMT study, Y chromosome-positive cells were found in glomeruli. The number of these cells was higher in the G-CSF-treated group than that in the saline-treated group. These findings indicate that BM cells are mobilized to damaged kidney tissue by G-CSF. Early reports showed that BM cells decreased inflammation in rats with acute myocardial infarction [40], and BM-derived mesenchymal stem cells suppressed inflammation through secretion of anti-inflammatory cytokines [41]. In addition, macrophage numbers did not differ significantly between the G-CSF- and saline-treated groups. These findings indicate that BM-derived cells are mobilized to damaged kidney tissue by G-CSF, as well as other cells such as macrophages, stem cells, and blood cells. Based on our results, we suggest that G-CSF prevents the progression of DN by mobilizing BM cells, rather than by a direct effect, because G-CSF is absent from glomeruli and BM cells are mobilized to damaged kidney tissue by G-CSF.

Sugimoto et al. have demonstrated that administration of pioglitazone for 6 months ameliorates renal injury, and Ko et al. showed that treatment with enalapril for 32 weeks had beneficial effects on renal damage due to diabetes [15,42]. We have confirmed that a relatively short G-CSF treatment (5 days) is effective and does not have severe side effects [43]. For this reason, G-CSF may be a promising drug for the treatment of DN.

This study has three limitations. First, investigating the main mechanism underlying the effect of G-CSF on early DN will need further investigations. To clarify the mechanism, illustration of a BM-dependent effect of G-CSF and analysis about downstream G-CSFR targets such as hematopoietic cell-specific Lyn substrate (HCLS)1, HCLS1-associated protein X (HAX)1, and lymphoid-enhancer binding factor (Lef)-1 in order to confirm no direct effect of G-CSF on early DN are needed. Second, the effects of G-CSF on the different stages of DN were not demonstrated. Finally, we did not establish the optimum dosage and regimen of G-CSF. In order to overcome this limitation, future studies should involve a larger number of animals.

In summary, we demonstrate that G-CSF could prevent the progression of early DN in OLETF rats. In addition, we speculate that mobilization of BM cells, rather than a direct effect of G-CSF, could be the mechanism of the observed G-CSF effect. This is the first report to show beneficial effects of G-CSF on early DN in an animal model. Our findings suggest that G-CSF has potential as a novel therapeutic drug in early DN patients.
Author Contributions
Conceived and designed the experiments: KSK BIS. Performed the experiments: BIS YSS JHP YJP. Analyzed the data: YSS KSK HK.

References
1. Aesaad KO, Herzenberg AM (2007) Distinguishing diabetic nephropathy from other causes of glomerulonephrosis: an update. J Clin Pathol 60: 18–26.
2. Giunti S, Barit D, Cooper ME (2006) Mechanisms of diabetic nephropathy: role of hypertension. Hypertension 49: 519–526.
3. Fukugawa Y, Watanabe Y, Inaguma D, Hotta N (1996) Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state. J Lab Clin Med 128: 568–578.
4. Adler S (1994) Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 5: 1165–1172.
5. Maier SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, et al. (1984) Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1149–1155.
6. Zohnholzer D, Ott I, Mellaion S, Schonig K, Michail F, et al. (2006) Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295: 1003–1010.
7. Sherdan WP, Moosry G, Wolf M, Dodds A, Lusk J, et al. (1989) Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2: 891–895.
8. Lee ST, Chu K, Jung KH, Ko SY, Kim EH, et al. (2005) Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res 1058: 120–128.
9. Hou SX, Jiang Y, Wang LF, Xu HY, Lin HM, et al. (2009) Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett 187: 40–44.
10. Yi-Sun S, Cheng-Hu F, Byung-Im S, Jun-Young P, Dae Woon J, et al. (2013) Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat. Ann Hepatol 12: 115–122.
11. Lim YH, Joe JH, Jang KS, Song YS, So BI, et al. (2011) Effects of granulocyte colony-stimulating factor (G-CSF) on diabetic cardiomyopathy in Osuka Long Evans Tokushima fatty rats. Cardiovasc Diabetol 10: 92.
12. Haagert M, Francoesa M, Vidal A, Bolanos N, Torras J, et al. (2012) Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes. Diabetologia 55: 2059–2068.
13. Kilkenny C, Browne WJ, Cuthi I, Emerson M, Altman DG (2013) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal experiments. Vet Clin Pathol 42: 27–31.
14. Shoji E, Okumura T, Onodera S, Takahashi N, Harada K, et al. (1997) Gastric emptying in OLETF rats not expressing CCK-A receptor gene. Dig Dis Sci 42: 513–519.
15. Sugimoto K, Tsurusaki S, Fujimura A (2001) Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties. Clin Exp Pharmacol Physiol 28: 626–630.
16. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, et al. (1995) The requirement of p53 for the extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 5: 1165–1172.
17. Ziyadeh FN (1993) The extracellular matrix in diabetic nephropathy. Kidney Int 44: 624–633.
18. Jefferson JA, Shankland SJ, Pichler RH (2000) Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 74: 22–36.
19. Mogensen CE (1987) Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31: 673–689.
20. Wolf G, Ziyadeh FN (1999) Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393–405.
21. Ziyadeh FN (2004) Mediators of diabetic renal disease: the case for TGF-Beta as the major mediator. J Am Soc Nephrol 15 Suppl 1: S55–57.
22. Navarro-Gonzalez JF, Mora-Fernandez C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433–442.
23. Harada M, Qin Y, Takano H, Ninamino T, Zou Y, et al. (2005) G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11: 305–311.
24. Park KW, Kwon VW, Cho HJ, Shin J, Kim YJ, et al. (2008) G-CSF exerts dual effects on endothelial cells–opposing actions of direct eNOS induction versus indirect cRPs elevation. J Mol Cell Cardiol 45: 670–678.
25. Wei Q, Hill WD, Su Y, Huang S, Dong Z (2011) Heme oxygenase-1 induction contributes to reno-protection by G-CSF during rhabdomyolysis-associated acute kidney injury. Am J Physiol Renal Physiol 301: F162–170.
26. Feng TC, Alison MR, Cook HT, Jeffery R, Wright NA, et al. (2005) Proliferation of bone marrow-derived cells contributes to regeneration after folic acid-induced acute tubular injury. J Am Soc Nephrol 16: 1723–1732.
27. Prodmoridi EL, Poulsom R, Jeffery R, Roilosse CA, Pollard PJ, et al. (2006) Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 24: 2448–2455.
28. Petit I, Szepesy-Kraitz V, Nagler A, Lahav M, Peled A; et al. (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCXR4. Nat Immunol 3: 687–690.
29. Tavarez AM, da Rosa Araujo AS, Baldo G, Matte U, Kharper N, et al. (2010) Bone marrow derived cells decrease inflammation but not oxidative stress in an experimental model of acute myocardial infarction. Life Sci 87: 699–706.
30. Ryan JM, Barry FP, Murphy JM, Mahon BP (2004) Mesenchymal stem cells avoid allogeneic rejection. J Immunol (Lond) 2: 85–91.
31. Ko GJ, Kang YS, Han SY, Lee MH, Song HK, et al. (2008) Preglizone attenuates diabetic nephropathy through a anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 23: 2750–2760.
32. Gabrilove JL, Hakobawiska A, Scher H, Sternberg C, Wong G, et al. (1988) Effect of granulocyte colony-stimulating factor on neutrophilia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414–1422.

Contributed reagents/materials/analysis tools: JHS YL HK. Wrote the paper: BIS YSS KSK.

Effects of G-CSF on Diabetic Nephropathy